Cargando…
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
Gene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert non-toxic prodrugs to cytotoxic drugs. A zone of cell kill around gene-modified cells due to transfer of toxic metabolites, known as the byst...
Autores principales: | Dachs, Gabi U., Hunt, Michelle A., Syddall, Sophie, Singleton, Dean C., Patterson, Adam V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255103/ https://www.ncbi.nlm.nih.gov/pubmed/19924084 http://dx.doi.org/10.3390/molecules14114517 |
Ejemplares similares
-
Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy
por: Green, Laura K, et al.
Publicado: (2013) -
Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol
por: Tupper, J, et al.
Publicado: (2004) -
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide(+)
por: Doloff, Joshua C, et al.
Publicado: (2010) -
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022) -
Bystander
por: Gorky, Maksim, 1868-1936
Publicado: (1930)